THE RELATIONSHIP BETWEEN GENE MUTATIONS AND PROGNOSIS IN PATIENTS WITH STAGE I NON-SMALL CELL LUNG CANCER AFTER SURGERY

This article discusses the relationship between gene mutations and prognosis in patients with stage I non-small cell lung cancer (NSCLC) after radical surgery. The study highlights that EGFR and ALK mutations are common in Stage I NSCLC patients and significantly affect both disease-free survival (DFS) and overall survival (OS). Patients with EGFR mutations respond well to EGFR-TKI treatment, significantly prolonging DFS; similarly, ALK mutation patients show improved prognosis with ALK inhibitor treatment. In contrast, patients with KRAS mutations have poorer outcomes, with common treatments including chemotherapy and immunotherapy. The importance of genetic testing in comprehensive postoperative treatment for early-stage NSCLC is highlighted, suggesting that individualized adjuvant therapy may play a role in improving long-term prognosis.